Home
1
News
2
最新消息
3
[2025/07] Exhibition announcement－ LYNTONIX promoted LTX-568 in 2025 BIO Aisa4
https://www.lyntonix.com/en/ LYNTONIX, INC.
LYNTONIX, INC. 17, Xuzhou Road, Room 936, Taipei, 100 Taiwan
According to Article 3, Paragraph 1 of “Regulations Governing the Identification of High-Risk Innovative Startups as Referred to in Article 12 of the Income Basic Tax Act”, LYNTONIX has been approved as a “High-Risk Innovative Startup”. Investments in LYNTONIX are therefore eligible for the Income Basic Tax credit. https://www.lyntonix.com/en/hot_522358.html [2025/03] News－ LYNTONIX has been approved as a High-Risk Innovative Starup by Industrial Development Administration (IDA), Ministry of Economic Affairs (MOEA), Taiwan 2025-09-05 2026-09-05
LYNTONIX, INC. 17, Xuzhou Road, Room 936, Taipei, 100 Taiwan https://www.lyntonix.com/en/hot_522358.html
LYNTONIX, INC. 17, Xuzhou Road, Room 936, Taipei, 100 Taiwan https://www.lyntonix.com/en/hot_522358.html
https://schema.org/EventMovedOnline https://schema.org/OfflineEventAttendanceMode
2025-09-05 http://schema.org/InStock TWD 0 https://www.lyntonix.com/en/hot_522358.html
News
Home News 最新消息 [2025/07] Exhibition announcement－ LYNTONIX promoted LTX-568 in 2025 BIO Aisa

LYNTONIX attended 2025 BIO Asia and showcased the latest research data on LTX-568. During the convention, LTX-568 received strong interest and highly positive feedback from industry experts and partners. The next step for LTX-568 is to complete the GLP preclinical studies, and advance to clinical trials. Our mission is clear：Let the IBS patients regain control of their lives. LYNTONIX will keep focusing on the effective and safe thetreatment of IBS abdominal pain.


Previous Back to List Next